Perifosine, a novel antitumor drug targeting AKT, is currently undergoing clinical trials and premarket development for various malignancies, including leukemia, lung cancer, and colorectal cancer [23, 32, 33]. The gene discussed is AKT1; the disease is lung carcinoma.